Pediatric cancer patients in clinical trials of sepsis: Factors that predispose to sepsis and stratify outcome

Robert Tamburro

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Objective: To delineate the factors that predispose pediatric oncology and hematopoietic stem cell transplant (HSCT) patients to sepsis and to identify factors that stratify their outcome. Data source: Peer-reviewed literature available via MEDLINE search. Study selection: All types of study. Conclusions: Pediatric oncology patients account for a relatively high proportion of severe sepsis in children. Available data suggest that outcomes among the non-HSCT oncology population are not substantially different from that of the general population. Data suggest that children with cancer (non-HSCT) who survive their septic episode will have a high probability of 6-month survival. In light of these findings, pediatric oncology patients are an important source of potential candidates for clinical trials of sepsis. In addition, HSCT patients seem to have significantly worse outcomes from sepsis than the non-HSCT oncology population, and thus, their participation in clinical trials is needed. However, in view of these worse outcomes, it is important to stratify the randomization for this population and to ensure that studies are adequately powered to assess outcomes in this subgroup.

Original languageEnglish (US)
Pages (from-to)S87-S91
JournalPediatric Critical Care Medicine
Volume6
Issue number3 SUPPL.
DOIs
StatePublished - May 1 2005

Fingerprint

Sepsis
Clinical Trials
Pediatrics
Transplants
Stem Cells
Neoplasms
Hematopoietic Stem Cells
Population
Information Storage and Retrieval
Random Allocation
MEDLINE
Survival

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Critical Care and Intensive Care Medicine

Cite this

@article{df1b9fb79f11470784a5986411dcfd65,
title = "Pediatric cancer patients in clinical trials of sepsis: Factors that predispose to sepsis and stratify outcome",
abstract = "Objective: To delineate the factors that predispose pediatric oncology and hematopoietic stem cell transplant (HSCT) patients to sepsis and to identify factors that stratify their outcome. Data source: Peer-reviewed literature available via MEDLINE search. Study selection: All types of study. Conclusions: Pediatric oncology patients account for a relatively high proportion of severe sepsis in children. Available data suggest that outcomes among the non-HSCT oncology population are not substantially different from that of the general population. Data suggest that children with cancer (non-HSCT) who survive their septic episode will have a high probability of 6-month survival. In light of these findings, pediatric oncology patients are an important source of potential candidates for clinical trials of sepsis. In addition, HSCT patients seem to have significantly worse outcomes from sepsis than the non-HSCT oncology population, and thus, their participation in clinical trials is needed. However, in view of these worse outcomes, it is important to stratify the randomization for this population and to ensure that studies are adequately powered to assess outcomes in this subgroup.",
author = "Robert Tamburro",
year = "2005",
month = "5",
day = "1",
doi = "10.1097/01.PCC.0000161288.00396.49",
language = "English (US)",
volume = "6",
pages = "S87--S91",
journal = "Pediatric Critical Care Medicine",
issn = "1529-7535",
publisher = "Lippincott Williams and Wilkins",
number = "3 SUPPL.",

}

Pediatric cancer patients in clinical trials of sepsis : Factors that predispose to sepsis and stratify outcome. / Tamburro, Robert.

In: Pediatric Critical Care Medicine, Vol. 6, No. 3 SUPPL., 01.05.2005, p. S87-S91.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pediatric cancer patients in clinical trials of sepsis

T2 - Factors that predispose to sepsis and stratify outcome

AU - Tamburro, Robert

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Objective: To delineate the factors that predispose pediatric oncology and hematopoietic stem cell transplant (HSCT) patients to sepsis and to identify factors that stratify their outcome. Data source: Peer-reviewed literature available via MEDLINE search. Study selection: All types of study. Conclusions: Pediatric oncology patients account for a relatively high proportion of severe sepsis in children. Available data suggest that outcomes among the non-HSCT oncology population are not substantially different from that of the general population. Data suggest that children with cancer (non-HSCT) who survive their septic episode will have a high probability of 6-month survival. In light of these findings, pediatric oncology patients are an important source of potential candidates for clinical trials of sepsis. In addition, HSCT patients seem to have significantly worse outcomes from sepsis than the non-HSCT oncology population, and thus, their participation in clinical trials is needed. However, in view of these worse outcomes, it is important to stratify the randomization for this population and to ensure that studies are adequately powered to assess outcomes in this subgroup.

AB - Objective: To delineate the factors that predispose pediatric oncology and hematopoietic stem cell transplant (HSCT) patients to sepsis and to identify factors that stratify their outcome. Data source: Peer-reviewed literature available via MEDLINE search. Study selection: All types of study. Conclusions: Pediatric oncology patients account for a relatively high proportion of severe sepsis in children. Available data suggest that outcomes among the non-HSCT oncology population are not substantially different from that of the general population. Data suggest that children with cancer (non-HSCT) who survive their septic episode will have a high probability of 6-month survival. In light of these findings, pediatric oncology patients are an important source of potential candidates for clinical trials of sepsis. In addition, HSCT patients seem to have significantly worse outcomes from sepsis than the non-HSCT oncology population, and thus, their participation in clinical trials is needed. However, in view of these worse outcomes, it is important to stratify the randomization for this population and to ensure that studies are adequately powered to assess outcomes in this subgroup.

UR - http://www.scopus.com/inward/record.url?scp=19444367955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444367955&partnerID=8YFLogxK

U2 - 10.1097/01.PCC.0000161288.00396.49

DO - 10.1097/01.PCC.0000161288.00396.49

M3 - Review article

C2 - 15857565

AN - SCOPUS:19444367955

VL - 6

SP - S87-S91

JO - Pediatric Critical Care Medicine

JF - Pediatric Critical Care Medicine

SN - 1529-7535

IS - 3 SUPPL.

ER -